Desflurane is an inhaled anesthetic gas used to put patients to sleep during surgery and keep them asleep throughout the procedure.[2] Suprane is currently approved and in use across 27 indications[4].[1]
Suprane is one of 380 small molecule programs targeting Fatigue. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
177 competitors in Obesity
Suprane
Cagrilintide
Decadron
Revlimid
Maridebart Cafraglutide
Berobenatide
Zenagamtide
Ribupatide
Semaglutide or Tirzepatide
Actemra
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Sep 18, 1992
SUPRANE
NDA NDA020118
Sep 18, 1992
SUPRANE
NDA NDA020118
Jul 5, 1995
SUPRANE
NDA NDA020118
Dec 16, 1997
SUPRANE
NDA NDA020118
Dec 9, 1998
SUPRANE
NDA NDA020118
Dec 2, 1999
SUPRANE
NDA NDA020118
Aug 8, 2002
SUPRANE
NDA NDA020118
May 8, 2006
SUPRANE
NDA NDA020118
Aug 14, 2006
SUPRANE
NDA NDA020118
Dec 15, 2006
SUPRANE
NDA NDA020118
Apr 14, 2009
SUPRANE
NDA NDA020118
Apr 5, 2010
SUPRANE
NDA NDA020118
Sep 23, 2013
SUPRANE
NDA NDA020118
Sep 27, 2013
SUPRANE
NDA NDA020118
Feb 26, 2015
SUPRANE
NDA NDA020118
Nov 4, 2016
SUPRANE
NDA NDA020118
Apr 27, 2017
SUPRANE
NDA NDA020118
Mar 1, 2019
SUPRANE
NDA NDA020118
Mar 1, 2019
SUPRANE
NDA NDA020118
Nov 1, 2022
SUPRANE
NDA NDA020118
Sources
Details